The increase in exercise capacity with the use of a fixed-dose combination of tiotropium and olodaterol in the Respimat inhaler has already been demonstrated in clinical studies in patients with chronic obstructive pulmonary disease (COPD). Italian authors evaluated its benefits in real-world practice and also focused on patient satisfaction with the inhaler.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
